Śledzińska Paulina, Bebyn Marek, Furtak Jacek, Koper Agnieszka, Koper Krzysztof
Molecular Oncology and Genetics Department, Innovative Medical Forum, The F. Lukaszczyk Oncology Center, 85-796 Bydgoszcz, Poland.
Department of Neurosurgery, 10th Military Research Hospital and Polyclinic, 85-681 Bydgoszcz, Poland.
Rev Neurosci. 2022 Sep 6;34(5):483-516. doi: 10.1515/revneuro-2022-0060. Print 2023 Jul 26.
Gliomas are the most common primary central nervous system tumors; despite recent advances in diagnosis and treatment, glioma patients generally have a poor prognosis. Hence there is a clear need for improved therapeutic options. In recent years, significant effort has been made to investigate immunotherapy and precision oncology approaches. The review covers well-established strategies such as surgery, temozolomide, PCV, and mTOR inhibitors. Furthermore, it summarizes promising therapies: tumor treating fields, immune therapies, tyrosine kinases inhibitors, IDH(Isocitrate dehydrogenase)-targeted approaches, and others. While there are many promising treatment strategies, none fundamentally changed the management of glioma patients. However, we are still awaiting the outcome of ongoing trials, which have the potential to revolutionize the treatment of glioma.
胶质瘤是最常见的原发性中枢神经系统肿瘤;尽管近年来在诊断和治疗方面取得了进展,但胶质瘤患者的预后通常较差。因此,显然需要改进治疗方案。近年来,人们在研究免疫疗法和精准肿瘤学方法方面付出了巨大努力。该综述涵盖了手术、替莫唑胺、PCV和mTOR抑制剂等成熟的策略。此外,它总结了有前景的疗法:肿瘤治疗电场、免疫疗法、酪氨酸激酶抑制剂、针对异柠檬酸脱氢酶(IDH)的方法等。虽然有许多有前景的治疗策略,但没有一种能从根本上改变胶质瘤患者的治疗方式。然而,我们仍在等待正在进行的试验结果,这些试验有可能彻底改变胶质瘤的治疗方法。